ADGRD1 and glioblastoma: Our previous work suggested that GPR133 expression is enriched in CD133-positive stem-like GBM cells.6 While the CD133-positive fraction is usually a minority of the total tumor cell population, the implication is that GPR133 is still expressed in CD133-negative cells, so that, overall, it is expressed in the majority of tumor cells.